Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00141206 |
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
Condition | Intervention | Phase |
---|---|---|
Smoking Cessation |
Drug: varenicline (CP-526,555) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation |
Estimated Enrollment: | 1005 |
Study Start Date: | May 2003 |
Study Completion Date: | April 2005 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Pfizer Investigational Site | |
Tucson, Arizona, United States | |
United States, California | |
Pfizer Investigational Site | |
Los Angeles, California, United States | |
Pfizer Investigational Site | |
Upland, California, United States | |
Pfizer Investigational Site | |
Newport Beach, California, United States | |
Pfizer Investigational Site | |
Riverside, California, United States | |
Pfizer Investigational Site | |
San Francisco, California, United States | |
United States, Connecticut | |
Pfizer Investigational Site | |
Farmington, Connecticut, United States | |
United States, Florida | |
Pfizer Investigational Site | |
Miami, Florida, United States | |
United States, Georgia | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States | |
United States, Illinois | |
Pfizer Investigational Site | |
Chicago, Illinois, United States | |
United States, Kentucky | |
Pfizer Investigational Site | |
Lexington, Kentucky, United States | |
United States, Louisiana | |
Pfizer Investigational Site | |
New Orleans, Louisiana, United States | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Worcester, Massachusetts, United States | |
United States, Nebraska | |
Pfizer Investigational Site | |
Omaha, Nebraska, United States | |
United States, New York | |
Pfizer Investigational Site | |
Brooklyn, New York, United States | |
Pfizer Investigational Site | |
Great Neck, New York, United States | |
United States, Oregon | |
Pfizer Investigational Site | |
Portland, Oregon, United States | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Philadelphia, Pennsylvania, United States | |
United States, Utah | |
Pfizer Investigational Site | |
Salt Lake City, Utah, United States | |
United States, West Virginia | |
Pfizer Investigational Site | |
Morgantown, West Virginia, United States |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A3051028 |
Study First Received: | August 30, 2005 |
Last Updated: | June 1, 2007 |
ClinicalTrials.gov Identifier: | NCT00141206 |
Health Authority: | United States: Food and Drug Administration |
Smoking Bupropion |
Habits |